ADRENALIN (epinephrine) by Pfizer is adrenergic alpha-agonists [moa]. First approved in 2012.
Drug data last refreshed 15h ago · AI intelligence enriched 18h ago
ADRENALIN (epinephrine) is a small-molecule alpha-adrenergic agonist administered via intramuscular, intravenous, or subcutaneous injection. It is the standard emergency treatment for anaphylaxis and acute allergic reactions, working by stimulating alpha-adrenergic receptors to rapidly reverse life-threatening symptoms. The product addresses a critical, time-sensitive medical need with no viable alternatives in acute care settings.
Peak lifecycle with stable Medicare utilization indicates mature, essential franchise requiring defensive strategy and operational excellence rather than aggressive growth initiatives.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Worked on ADRENALIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moADRENALIN is a legacy, essential-care product offering stable but limited career growth; roles focus on defending market share, optimizing market access, and managing the transition to genericization rather than driving expansion. Professionals joining this team should expect operational excellence focus, complex insurance/payer negotiations, and preparation for post-LOE portfolio repositioning.